Liver Disease Therapeutics Market To Reach $28.62 Billion By 2030

Liver Disease Therapeutics Market Growth & Trends

The global liver disease therapeutics market is expected to be valued at USD 28.62 billion by 2030, registering a CAGR of 5.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments’ and big companies’ vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

 Request a free sample copy or view report summary: Liver Disease Therapeutics Market Report

Liver Disease Therapeutics Market Report Highlights

• The antiviral drugs segment dominated the market in the global liver disease therapeutics market with a revenue share of 30.3% in 2023. The high incidence of hepatitis diseases contributes to the rise in liver disease cases.

• The targeted therapy segment is expected to register the fastest CAGR of 7.2% over the forecast period, driven by the rising incidence of liver diseases and geriatric population globally.

• The hepatitis segment dominated the global liver disease therapeutics market with a revenue share of 36.6% in 2023.

• Non-alcoholic fatty liver disease (NAFLD) is expected to register the fastest growth over the forecast period with a CAGR of 6.6%. Segment growth is fueled by the increasing prevalence of obesity and associated fat accumulation in liver cells.

• North America liver disease therapeutics market dominated the global liver disease therapeutics market with a revenue share of 38.4% in 2023.

• Asia Pacific liver disease therapeutics market is expected to have the fastest growth in the forecast period with a CAGR of 7.4%.

Liver Disease Therapeutics Market Segmentation

Grand View Research has segmented global liver disease therapeutics market report based on drug class, disease, and region:

Liver Disease Therapeutics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Antiviral Drugs

• Vaccines

• Chemotherapy

• Targeted Therapy

• Immunosuppressants

• Immunoglobulins

• Corticosteroids

• Other Products

Liver Disease Therapeutics Disease Outlook (Revenue, USD Million, 2018 - 2030)

• Hepatitis

• Autoimmune Diseases

• Non-alcoholic Fatty Liver Disease (NAFLD)

• Cancer

• Genetic Disorders

• Other Diseases

Liver Disease Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Liver Disease Therapeutics Market

• Gilead Sciences, Inc.

• AbbVie Inc.

• Bristol-Myers Squibb Company

• F. Hoffmann-La Roche Ltd

• Takeda Pharmaceutical Company Limited

• Gilead Sciences, Inc.

• Johnson & Johnson Services, Inc.

• Merck & Co., Inc.

• Novartis AG

• Pfizer Inc.

• Sanofi

• AbbVie Inc.

• Bristol-Myers Squibb Company

• GlaxoSmithKline PLC